Once-daily, oral chelation with deferasirox (Exjade®, ICL670) provides sustained protection from labile plasma iron in 2-thalassemia patients

被引：0
|
作者：
Daar, S.
Taher, A.
Pathare, A.
Nick, H.
Krahn, U.
Hadler, D.
机构：
[1] Sultan Qaboos Univ, Muscat, Oman
[2] Amer Univ Beirut, Beirut, Lebanon
[3] Novartis, Basel, Switzerland
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2007年 / 82卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：513 / 514
页数：2
相关论文
共 43 条
  • [41] Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration
    Lu, Meng-Yao
    Wang, Ning
    Wu, Wen-Hsin
    Lai, Cheng-Wei
    Kuo, Pei-Hsin
    Chiang, Po-Hung
    Lin, Kai-Hsin
    Wu, Tzu-Hua
    CLINICAL THERAPEUTICS, 2015, 37 (08) : 1751 - 1760
  • [42] IRON CHELATION THERAPY WITH DEFERASIROX (EXJADE®) IN REDUCING CARDIAC SIDEROSIS IN β-THALASSEMIA PATIENTS: 2-YEAR RESULTS FROM THE EPIC CARDIAC SUBSTUDY
    Pennell, Dudley J.
    Porter, John
    Cappellini, Domenica
    Chan, Lee Lee
    El-Beshlawy, Amal
    Aydinok, Yesim
    Ibrahim, Hishamshah
    Li, Chi-Kong
    Viprakasit, Vip
    Elalfy, Mohsen
    Kattamis, Antonis
    Smith, Gillian
    Habr, Dany
    Domokos, Gabor
    Roubert, Bernard
    Taher, Ali
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [43] Deferasirox (Exjade®), the Once-Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5-Year Follow-up.
    Vichinsky, Elliott
    Coates, Thomas
    Thompson, Alexis A.
    Bernaudin, Francoise
    Rodriguez, Martha
    Rojkjaer, Lisa
    Heeney, Matthew M.
    BLOOD, 2008, 112 (11) : 506 - 506
12345